10.6084/m9.figshare.7587365.v1
Bixia Tang
Bixia
Tang
Xieqiao Yan
Xieqiao
Yan
Xinan Sheng
Xinan
Sheng
Lu Si
Lu
Si
Chuanliang Cui
Chuanliang
Cui
Yan Kong
Yan
Kong
Lili Mao
Lili
Mao
Bin Lian
Bin
Lian
Xue Bai
Xue
Bai
Xuan Wang
Xuan
Wang
Siming Li
Siming
Li
Li Zhou
Li
Zhou
Jiayi Yu
Jiayi
Yu
Jie Dai
Jie
Dai
Kai Wang
Kai
Wang
Jinwei Hu
Jinwei
Hu
Lihou Dong
Lihou
Dong
Haifeng Song
Haifeng
Song
Hai Wu
Hai
Wu
Hui Feng
Hui
Feng
Sheng Yao
Sheng
Yao
Zhihong Chi
Zhihong
Chi
Jun Guo
Jun
Guo
Additional file 1: of Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
Springer Nature
2019
PD-1
Monoclonal antibody
JS001
Melanoma
Urothelial cancer
Renal cell carcinoma
2019-01-14 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Safety_and_clinical_activity_with_an_anti-PD-1_antibody_JS001_in_advanced_melanoma_or_urologic_cancer_patients/7587365
Figure S1. Phase I study schema of JS001 in advanced melanoma, renal cell carcinoma, and urothelial carcinoma. Figure S2. The PK profiles of JS001 in humans. Figure S3. The percentage of activated CD8+ T cell population during JS001 treatment. Figure S4. Correlation of tumor mutational burden (TMB) with clinical efficacy. Table S1. Treatment-related serious adverse events (SAE). Table S2. Grade 3 and above treatment-related adverse events (TRAE) in each cohort. Table S3. PD-1 receptor occupancy (RO) by JS001 in three dose cohorts. Table S4. Subgroup analysis of correlation with clinical efficacy. Table S5. Tumor mutational burden measurement and correlation with clinical response. (DOCX 575Â kb)